Streetbeat News

Stock Prices

JAZZ

HC Wainwright & Co. has maintained its Buy rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) but lowered its price target from $204 to $200. Despite this, shares of Jazz Pharmaceuticals have seen a slight increase of 0.2% in the last 24 hours, trading at $118 per share. A move to the new price target would represent a 69.49% increase from the current share price. Jazz Pharmaceuticals, an Ireland-based biopharmaceutical company, focuses on treatments for sleeping disorders and oncology, with nine approved drugs in its portfolio.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 5:00 pm

CMS

Barclays has maintained its Equal-Weight rating on CMS Energy (NYSE:CMS) and increased its price target from $57.00 to $58.00. CMS Energy's shares are currently trading at $58.80, indicating a potential 1.36% decline to the new target. CMS Energy, an energy holding company, operates through its regulated utility, Consumers Energy, and CMS Enterprises, focusing on natural gas, electric service, and renewable energy generation.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 5:00 pm

RPM

UBS has maintained its Neutral rating on RPM International Inc (NYSE:RPM) but raised its price target from $111.00 to $121.00. RPM Intl's shares are currently trading at $117.89, and the new price target suggests a potential upside of 2.64%. RPM International Inc is a manufacturer of paints, coatings, and adhesives with the majority of its revenue coming from North America.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 5:00 pm

RCMT

RCM Technologies' shares dropped following the announcement of disappointing Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 4:54 pm

IMRX

Immuneering's shares dropped following the announcement of topline results from the Phase 1 portion of its Phase 1/2a clinical trial of IMM-1-104 in advanced RAS-mutant solid tumors.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 4:52 pm

ENCVF

KKR

KKR & Co (NYSE:KKR) is set to launch a voluntary public takeover offer for Encavis AG (OTC:ENCVF) with an equity value of approximately €2.8 billion, offering €17.50 per share. This offer represents a significant premium over Encavis's current share price. Abacon Capital and other shareholders have agreed to sell about 31% of Encavis shares to KKR's investment vehicle, Elbe Bidco. Additionally, the Viessmann family will co-invest in the consortium. The deal aims to expand Encavis's capacity to 7 GW by 2027 and is contingent on a minimum acceptance threshold of 54.285%. KKR's cash and investments were reported at $29 billion as of FY23-end. KKR shares dropped by 0.83% to $97.14.

Portfolio Pulse from Lekha Gupta

March 14, 2024 | 4:48 pm

DOGEUSD

SHIBUSD

SOLUSD

The 'Jeo Boden' meme coin, inspired by a humorous misspelling of U.S. President Joe Biden's name, surged 252% in value on the Solana blockchain, leading to a broader interest in meme coins including Dogecoin and Shiba Inu. This trend coincides with Bitcoin reaching new price highs, indicating a growing interest in cryptocurrency investments. A notable investor, Barkery, turned a $260 investment into $423,000 by trading BODEN tokens.

Portfolio Pulse from Murtuza Merchant

March 14, 2024 | 4:47 pm

AAPL

SPY

TSLA

USO

The article discusses the current financial market trends, highlighting hotter Producer Price Index (PPI) data indicating higher inflation at the producer level than expected, and declining retail sales suggesting weakening consumer spending. It mentions the positive early trade money flows in several major tech companies and ETFs, while Tesla and NVIDIA experience negative flows. The International Energy Agency predicts an oil supply deficit throughout 2024, contrary to previous surplus expectations. The article advises investors to consider a more defensive position within the protection band to balance market crosscurrents.

Portfolio Pulse from The Arora Report

March 14, 2024 | 4:47 pm

PBM

Psyence Biomedical shares are trading higher following the Indiana legislature's decision to send a bill to the governor that includes funding for psilocybin clinical research trials.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 4:46 pm

RTX

Options market activity for RTX (NYSE:RTX) shows a bearish sentiment among investors, with 68% of trades being bearish. The trading activity suggests an expected price range of $70.0 to $120.0 for RTX in the next three months. RTX, a major aerospace and defense company, is currently trading at $91.6, up 1.15%, with an RSI indicating it may be approaching overbought territory. An analyst from Wells Fargo has upgraded RTX to Overweight with a price target of $120.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 4:45 pm